期刊档案 · BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY
Human Vaccines & Immunotherapeutics
ISSN 1554-8600 · eISSN 2164-554X · TAYLOR & FRANCIS INC · UNITED STATES · Monthly · 创刊 2005
Human Vaccines & Immunotherapeutics 中科院 医学 3区(2025 年升级版),影响因子 4.13,JCR Q2(官网公布),订阅期刊,收取 APC,金额未公布,近 24 个月 100 篇文章投稿到接收中位 95 天,录用比例约50%(社区反馈),年发文 514 篇,SCIE 收录。
研究范围
研究范围与定位
Human Vaccines & Immunotherapeutics 由 TAYLOR & FRANCIS INC 出版,属中科院医学大类(2025 升级版3区)。按 OpenAlex 近年发文统计,该刊主要发表 Vaccine Coverage and Hesitancy、Influenza Virus Research Studies、Bacterial Infections and Vaccines 等主题的论文,这 3 个主题约占 28.1%,主导子领域为 Epidemiology。(根据 OpenAlex 主题统计与中科院分区数据生成)
Human Vaccines & Immunotherapeutics is an open access peer-reviewed journal publishing international research into human vaccinology and immunotherapy, including novel and experimental vaccine and immunotherapeutics exploration. The journal's audience includes clinicians, researchers, medical professionals, epidemiologists, public health workers, biotech and pharmaceutical companies, and drug regulators interested in vaccinology and immunotherapy. Human Vaccines & Immunotherapeutics is affiliated with the International Society for Vaccines (ISV) and the Association for Cancer Immunotherapy (CIMT). The aim of Human Vaccines & Immunotherapeutics is to provide a platform to present and discuss developments in human vaccinology and immunotherapy. The journal covers the following topics: Research and development and new technologies for novel vaccines and immunotherapeutics Vaccines and immunotherapeutics for treating both infectious and non-infectious diseases, e.g. cancer Preclinical studies and assays Clinical trials for vaccines and immunotherapeutics Disease processes and mechanisms, including biomarkers Licensed products and their use in the field Knowledge, attitude, practices, acceptance and hesitation for vaccination and immunotherapy Interventions and policy Impact of licensed vaccines and immunotherapeutics on disease and health economics Safety and surveillance of licensed vaccines and immunotherapeutics Prevention and treatment in the developing world Epidemiology and pharmaco-economics Human Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rapid Communications, Data Notes, Article Commentaries, Meeting Reports, Plain Language Summaries of Publication and Editorials (Editors and Guest Advisors only) for publication. The journal operates a single-anonymized peer review policy. Note that bibliometric studies will only occasionally be considered and must provide a deep, rigorous analysis of current and future topics in order to bring value to the field. Bibliometric studies must be validated using the authors' own data through replication in an original sample. Pharmacological and bioinformatics studies based solely on in silico analyses without experimental validation are not considered. The Journal does not accept Traditional Chinese Medicine studies. The journal accepts replication studies, provided that the study adds significantly to the body of
摘自期刊官网 Aims & Scope
研究方向(LetPub):BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY
主编 Ronald Ellis出版商官网
编委会国家分布:中国大陆 22 位(约 20%);主要国家 美国 35、中国 22、意大利 8、澳大利亚 6、英国 5(共 111 位编委标注了国家) 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计,占比为近似值
- Vaccine Coverage and HesitancySocial Sciences11.1%
- Influenza Virus Research StudiesMedicine9.5%
- Bacterial Infections and VaccinesImmunology and Microbiology7.5%
- Pneumonia and Respiratory InfectionsMedicine6.8%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.6%
- Hepatitis B Virus StudiesMedicine5.3%
- SARS-CoV-2 and COVID-19 ResearchMedicine4.7%
- Viral gastroenteritis research and epidemiologyMedicine4.6%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表( 2025年3月升级版)医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 生物工程与应用微生物BIOTECHNOLOGY & APPLIED MICROBIOLOGY | 3 区 |
| 小类 | 免疫学IMMUNOLOGY | 3 区 |
Top 期刊:否综述期刊:否
《新锐期刊分区表》( 2026年3月发布)医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 生物工程与应用微生物BIOTECHNOLOGY & APPLIED MICROBIOLOGY | 2 区 |
| 小类 | 免疫学IMMUNOLOGY | 3 区 |
Top 期刊:否综述期刊:未标注
期刊分区表( 2023年12月旧的升级版)医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 生物工程与应用微生物BIOTECHNOLOGY & APPLIED MICROBIOLOGY | 3 区 |
| 小类 | 免疫学IMMUNOLOGY | 4 区 |
Top 期刊:否综述期刊:否
期刊官网公布的 JCR / CiteScore 分区
- JCR Q2 · 最佳分区 · 2025 年度
- CiteScore Q1 · 2025 年度
出版商自述数据,JCR 以 Clarivate、CiteScore 以 Scopus 公布为准;与中科院分区是不同体系。出版商官网
数据库收录
SCIELetPub
国际期刊预警名单:各版本均未列入LetPub
期刊官网自述收录
Web of ScienceScopusMEDLINEPubMedEmbaseDOAJ出版商官网
其他:Adis International Ltd. - Reactions Weekly (Online)、EBSCOhost - Biological Abstracts (Online)、Thomson Reuters - Biological Abstracts (Online)
期刊官网列出的收录清单,未与各数据库逐一核对;Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 4.13LetPub ·
- 影响因子(出版商公布) 2025
- 4.2出版商官网 ·
- 五年影响因子(出版商公布) 2025
- 3.7出版商官网 ·
- CiteScore(出版商公布) 2025
- 7.4出版商官网 ·
- SJR(出版商公布) 2025
- 1.09出版商官网 ·
- SNIP(出版商公布) 2025
- 1.08出版商官网 ·
- h-index
- 74OpenAlex ·
- i10-index
- 492OpenAlex ·
- 两年平均被引
- 0OpenAlex ·
- 自引率
- 9.5%LetPub ·
- Gold OA 文章占比
- 100%LetPub ·
发文规模
- 年文章数
- 514LetPub ·
- 年下载量(出版商公布)
- 3,600,000出版商官网 ·
- 年下载量(出版商公布) 2025
- 3,600,000出版商官网 ·
不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 Crossref 登记的稿件日期 · 至
95 天投稿到接收中位数 · P25–P75 75 天 – 124 天
- 接收到上线
- 中位数 15 天(100 篇)
- 投稿到上线
- 中位数 119 天
- 样本
- 100 篇有投稿与接收日期的文章(窗口内共 1,105 篇),最近一篇接收于
只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度(社区反馈)
- 平均2月LetPub ·
- 平均录用比例(社区反馈)
- 50%LetPub ·
- 录用率(出版商公布)
- 50%出版商官网 ·
- 录用率(出版商公布) 2025
- 50%出版商官网 ·
- 投稿到首次决定
- 27 天出版商官网 ·
- 投稿到首次决定 2025
- 27 天出版商官网 ·
- 外审后首次决定
- 49 天出版商官网 ·
- 外审后首次决定 2025
- 49 天出版商官网 ·
- 接收到发表
- 16 天出版商官网 ·
- 接收到发表 2025
- 16 天出版商官网 ·
- 评审方式
- 单盲同行评审出版商官网
社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
订阅期刊,文章需订阅或购买阅读,通常不收取版面费。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| 出版商官网 | 有,金额未公布 | — | — |
费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。
投稿要求
文章类型与投稿政策(官网)
投稿准备要点1 项,摘自作者指南
- 不接收
- Traditional Chinese Medicine studies
接收的文章类型21 种
- article commentariesHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- article commentaryHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- case reportHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- case reportsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- data noteHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- data notesHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- editorialHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- editorialsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- meeting reportHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- meeting reportsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- methodsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- plain language summaries of publicationHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- plain language summary of publicationHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- product reviewHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- product reviewsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- rapid communicationHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- rapid communicationsHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- research articleHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- research articlesHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- review articleHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
- review articlesHuman Vaccines & Immunotherapeutics accepts Research Articles, Review Articles (including State of the Art Reviews), Methods, Product Reviews, Case Reports, Rap…未说明篇幅
官网政策摘录数据可用性、开放获取、同行评审
- 数据可用性
该期刊实行“经合理请求共享”的数据共享政策。 模型中文摘要
The journal also now has a Share Upon Reasonable Request data sharing policy.
原文 ↗出版商官网 ·- 开放获取 Open access
《Human Vaccines & Immunotherapeutics》是一本开放获取期刊,仅发表开放获取文章,文章在出版后可立即免费在线获取。 模型中文摘要
Human Vaccines & Immunotherapeutics is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers, no…
原文 ↗出版商官网 ·- 同行评审
该期刊实行单盲同行评审政策。 模型中文摘要
The journal operates a single-anonymized peer review policy.
原文 ↗出版商官网 ·
摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。
基本信息
出版信息与官方入口
- 出版商
- TAYLOR & FRANCIS INC
- 出版国家或地区
- UNITED STATES
- 出版语言
- English
- 出版周期
- Monthly
- 创刊年份
- 2005
- ISSN
- 1554-8600
- 印刷版 ISSN
- 2164-5515
- 电子版 ISSN
- 2164-554X
- 官网最新一期
- Volume 22, Issue 1(2026 年)
- 官方链接
- 期刊主页 ↗LetPub
- 投稿系统 ↗出版商官网
- 专刊 / 特刊征稿 ↗出版商官网
常见问题
关于 Human Vaccines & Immunotherapeutics 的常见问题
Human Vaccines & Immunotherapeutics 是中科院几区期刊?
2025 年升级版分区表中,Human Vaccines & Immunotherapeutics 为医学 3区,小类 生物工程与应用微生物 / 免疫学 3 区。2026 年新锐版分区表中为医学 3区。不同版本与大小类分区不能混用。
Human Vaccines & Immunotherapeutics 的影响因子是多少?
LetPub 汇总的最新公布影响因子为 4.13,h-index 为 74。
Human Vaccines & Immunotherapeutics 的审稿周期多长?
按 2024年10月至2026年10月(近 24 个月)100 篇已发表文章登记的日期,投稿到接收的中位数为 95 天(四分位 75–124 天);投稿社区反馈的平均审稿速度为约 2 个月,平均录用比例反馈为“约50%”;期刊官网公布的录用率为 50%(2025)。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。
Human Vaccines & Immunotherapeutics 是 JCR 几区?
期刊官网公布的 JCR 分区为 Q2(最佳分区)。JCR 分区以 Clarivate 公布为准,与中科院分区是不同体系;该刊中科院分区为医学 3区。
Human Vaccines & Immunotherapeutics 的编委会里有中国学者吗?
期刊官网编委会页面上标注了国家的 111 位编委中,中国大陆 22 位(约 20%);人数最多的国家是 美国(35 位)、中国(22 位)、意大利(8 位)。统计按编委会页面列出的机构国家计,仅供参考。
Human Vaccines & Immunotherapeutics 被哪些数据库收录?
据 LetPub 与 DOAJ 记录,Human Vaccines & Immunotherapeutics 被 SCIE 收录。期刊官网自述还被 Web of Science、Scopus、MEDLINE、PubMed、Embase、DOAJ 收录,该清单未与各数据库逐一核对。
Human Vaccines & Immunotherapeutics 是开放获取期刊吗?版面费多少?
Human Vaccines & Immunotherapeutics 为订阅期刊。收取 APC,金额未公布。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-25 归档)。最近更新:。